C4 therapeutics appoints accomplished oncology executive steve hoerter to board of directors

Hoerter brings over three decades of oncology commercialization and leadership experience appointment underscores continued transformation of board to lead c4t into next phase of pipeline progress watertown, mass., nov. 20, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its board of directors with the appointment of steve hoerter as a director.
CCCC Ratings Summary
CCCC Quant Ranking